Table 1 Differences in the clinical features of patients with HCM between the VPS and Non-VPS groups
Factors | Non-VPS group (n = 57) | VPS group (n = 29) | P-value |
|---|---|---|---|
Sex (male), n (%) | 52 (91.2%) | 26 (89.7%) | 0.812 |
Age (years) | 34.3 ± 5.0 | 34.5 ± 9.0 | 0.438 |
BMI | 19.95 ± 2.9 | 20.58 ± 2.9 | 0.309 |
Interval from symptom onset to the initiation of anticryptococcal therapy (days) | 10.0 (1.5–27.0) | 10.0 (5.5–22.5) | 0.985 |
Blood cryptococcus culture positivity, n (%) | 19 (33.3%) | 9 (31.0%) | 0.830 |
Clinical manifestations, n (%) | |||
Fever | 35 (61.4%) | 16 (55.2%) | 0.578 |
Headache | 38 (66.7%) | 21 (72.4%) | 0.587 |
Dizziness | 6 (10.5%) | 7 (24.1%) | 0.096 |
Seizures | 2 (3.5%) | 6 (20.7%) | 0.010 |
Vomiting | 15 (26.3%) | 13 (44.8%) | 0.083 |
Vision loss | 3 (5.3%) | 2 (6.9%) | 0.76 |
Hearing loss | 2 (3.5%) | 2 (6.9%) | 0.481 |
Disturbance of consciousness | 7 (12.3%) | 2 (6.9%) | 0.441 |
First CSF assay | |||
ICP (mmH2O) | 300.0 (195.0–400.0) | 335.0 (252.5–416.3) | 0.446 |
Glucose (mmol/L) | 2.5 (1.9–2.9) | 2.4 (1.7–3.3) | 0.866 |
Total protein (g/L) | 0.6 (0.4–0.9) | 0.6 (0.4–1.0) | 0.98 |
WBC count (× 106/L) | 10.0 (2.8–34.0) | 3.0 (0–20.0) | 0.084 |
Chlorine (mmol/L) | 116.4 ± 6.3 | 119.7 ± 5.6 | 0.192 |
Cryptococcus neoformans count (/HPF) | 3.0 (0.8–28.5) | 3.0 (0.0–27.0) | 0.213 |
Positive India ink staining, n (%) | 47 (82.5%) | 25 (86.2%) | 0.656 |
Positive Cryptococcus culture, n (%) | 48 (84.2%) | 27 (93.1%) | 0.243 |
Blood test results | |||
C-reactive protein (mg/L) | 6.05 (3.2–24. 0) | 7.8 (3.4–18.8) | 0.82 |
WBC (× 109/L) | 5.0 (3.3–6.7) | 5.8 (4.4–7.8) | 0.084 |
Hemoglobin (g/L) | 124.4 ± 27.5 | 123.3 ± 21.8 | 0.853 |
Platelet (× 109/L) | 204. 9 ± 77.1 | 218.2 ± 116.1 | 0.526 |
Albumin (g/L) | 38.4 (33.4–42.9) | 39.1 (37.2–40.4) | 0.594 |
CD4 (/mL) | 27.5 (13.0–41.8) | 11.0 (6.0–24.8) | 0.386 |